Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib (Q39890184)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib |
scientific article |
Statements
1 reference
Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib (English)
1 reference
Troy A Luster
1 reference
Jeffrey A Carrell
1 reference
Kathy McCormick
1 reference
David Sun
1 reference
Robin Humphreys
1 reference
27 January 2009
1 reference
1 reference
8
1 reference
2
1 reference
292-302
1 reference
Identifiers
1 reference
1 reference